EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte Studie

Blood Pressure Parameters and Risk of Cognitive Decline and Dementia in Type 2 Diabetes: Results From the ADVANCE Trial

Sultana Shajahan iD, Mark Woodward iD, Craig S Anderson iD, Cheryl Carcel iD, Nelson Wang, Phillip J Tully, Ruth Peters iD, Stephen Harrap, Neil Poulter iD, Giuseppe Mancia iD, Stephen MacMahon, John Chalmers iD und 1 weitere

Journal of the American Heart Association · 2026

DOI: 10.1161/jaha.125.044061 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of the American Heart Association, 2026. Verfasst von Sultana Shajahan und 12 weiteren Autor:innen. Beteiligte Einrichtung: The George Institute for Global Health University of New South Wales Sydney NSW Australia. Hauptthemen laut MEDLINE: Blood Pressure, Cognition, Cognitive Dysfunction, Dementia. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 71 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Blood pressure (BP) variability and cumulative BP load are significantly associated with cardiovascular disease risk beyond mean systolic BP, but less is known regarding their associations with cognitive decline/dementia and whether these associations differ by cognitive function at baseline or by sex. The aims of this study were to determine associations of different BP parameters with cognitive decline/dementia in patients with type 2 diabetes and explore differences by mild cognitive impairment at baseline and sex.

Methods

Using data from the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation) study, BP parameters were calculated from an 18‐month exposure window comprising measurements at 3, 4, 6, 12, and 18 months, after randomization. Logistic regression was used to estimate the odds ratio (OR) per SD higher and 95% CI for the associations of BP parameters with the composite outcome of cognitive decline (≥3 points from baseline on the Mini‐Mental State Examination) or clinical diagnosis of dementia.

Results

Of the 11 140 ADVANCE participants, 9586 patients had 5 complete BP measurements within the 18‐month exposure window. After a mean follow‐up of 3.5 years, 1674 (17.5%) participants were diagnosed with cognitive decline and/or dementia. Overall, variability and baseline pulse pressure (PP), but not BP load, were associated with higher odds of cognitive decline/dementia (OR: variability in systolic BP, 1.11 [95% CI, 1.05–1.17]; diastolic BP, 1.11 [95% CI, 1.05–1.17]; PP, 1.05 [95% CI, 1.00–1.11]; mean arterial pressure, 1.13 [95% CI, 1.07–1.19]; and baseline PP, 1.19 [95% CI, 1.13–1.25]). There were no differences by mild cognitive impairment at baseline or sex.

Conclusions

Higher BP variability and baseline PP, but not mean BP or BP load, were associated with higher odds of cognitive decline/dementia in patients with type 2 diabetes. BP variability and PP may be important therapeutic markers for the preservation of brain health. Registration URL: https://clinicaltrials.gov ; Unique Identifier: NCT00145925.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood PressureCognitionCognitive DysfunctionDementiaDiabetes Mellitus, Type 2HypertensionAgedFemaleHumansMaleMiddle AgedAntihypertensive AgentsRisk AssessmentRisk FactorsTime Factors

Stichwörter der Autor:innen

blood pressurecognitive declinedementiatype 2 diabetesvariability

Substanzen

Antihypertensive Agents

Autor:innen und Institutionen

  • The George Institute for Global Health University of New South Wales Sydney NSW Australia.
  • The George Institute for Global Health, School of Public Health, Imperial College London London United Kingdom.
  • Institute of Science and Technology for Brain-inspired Intelligence, Fudan University Shanghai China.
  • Neurology Department Royal Prince Alfred Hospital Sydney NSW Australia.
  • Prince of Wales Clinical School University of New South Wales Sydney NSW Australia.
  • School of Psychology Deakin University Burwood VIC Australia.

ORCID-Profile: Sultana Shajahan, Mark Woodward, Craig S Anderson, Cheryl Carcel, Ruth Peters, Neil Poulter, Giuseppe Mancia, John Chalmers, Katie Harris

Zitieren

APA

Shajahan, S., Woodward, M., Anderson, C. S., Carcel, C., Wang, N., Tully, P. J., Peters, R., Harrap, S., Poulter, N., Mancia, G., MacMahon, S., Chalmers, J., & Harris, K. (2026). Blood Pressure Parameters and Risk of Cognitive Decline and Dementia in Type 2 Diabetes: Results From the ADVANCE Trial. Journal of the American Heart Association. https://doi.org/10.1161/jaha.125.044061

Vancouver

Shajahan S, Woodward M, Anderson CS, Carcel C, Wang N, Tully PJ, et al. Blood Pressure Parameters and Risk of Cognitive Decline and Dementia in Type 2 Diabetes: Results From the ADVANCE Trial. Journal of the American Heart Association. 2026. doi:10.1161/jaha.125.044061

BibTeX
@article{Shajahan2026,
  author = {Shajahan, Sultana and Woodward, Mark and Anderson, Craig S and Carcel, Cheryl and Wang, Nelson and Tully, Phillip J and Peters, Ruth and Harrap, Stephen and Poulter, Neil and Mancia, Giuseppe and MacMahon, Stephen and Chalmers, John and Harris, Katie},
  title = {Blood Pressure Parameters and Risk of Cognitive Decline and Dementia in Type 2 Diabetes: Results From the ADVANCE Trial},
  journal = {Journal of the American Heart Association},
  year = {2026},
  doi = {10.1161/jaha.125.044061}
}
Kostenlos starten →